Nearly three years after the FDA approved Pfizer's bispecific antibody Elrexfio as a late-line treatment for patients with ...

Results from the MagnetisMM-5 study showed that Elrexfio significantly improved progression-free survival, which means ...

Pfizer’s Phase 3 MagnetisMM-5 trial found that Elrexfio (elranatamab) significantly improved progression-free survival over a ...

(NYSE: PFE) today announced positive topline results from the Phase 3 MagnetisMM-5 study evaluating ELREXFIO ® (elranatamab) as monotherapy in adults with relapsed or refractory multiple myeloma (RRMM ...

Pfizer (PFE) stock is in focus as a trial for the company's Elrexfio multiple myeloma drug hit the main goal with patients on ...

April 29 () - Pfizer said on Wednesday its drug Elrexfio met the main goal in ‌a late-stage trial that tested the blood ...

Pfizer announces positive results from phase 3 MagnetisMM-5 study of Elrexfio as monotherapy in adults with relapsed or refractory multiple myeloma: New York Thursday, April 30, 2 ...

Pfizer said its blood-cancer treatment met the main goal of an ongoing late-stage study, significantly extending the time patients lived without their disease worsening compared with a standard drug ...

Pfizer has shared promising phase 2 results of its Elrexfio (elranatamab-bcmm) monotherapy in patients with heavily pre-treated relapsed or refractory multiple myeloma (RRMM) as part of its ongoing ...

Pfizer’s multiple myeloma drug Elrexfio met its main goal in a late-stage trial, delivering a statistically significant and clinically meaningful improvement in progression-free survival over standard ...